question management
numer compani meet take place san francisco next week
assembl top list question believ key discuss manag
cover compani go
report contain key question manag
question begin page report
thing look next week
expect potenti updat strategy/bd initi street seek proactiv capit
alloc new manag team enabl growth visibl
like pre-report next week see possibl anoth beat con
like pre-report next week expect updat aadc screen effort preval rate
gt-aadc bla file possibl dystrophin data translarna implic approv
color commerci launch strategi caplyta
clariti ph iii trial amend rainforest redwood initi
regulatori feedback role registr packag mdd and/or follow ph iii
willing settl tecfidera ip disput updat aducanumab regulatori interact
pre-report recent year though may possibl could provid favor
indic next week given strong trikafta rx trend sinc launch eu reimburs
potenti updat microdystrophin studi enrol high-dos lgmd
progress/safeti timelin updat manufactur scale-up microdystrophin
host dinner manag monday januari sf look
addit color progress updat registr trial azacitidin md
ahead key data
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
addit aducanumab data analysi could expect see engag
emerg prime studi expect file bla base
case expect adcomm conven bla accept see initi
approv non-carri due lower rate aria group plausibl
outcom fda review
launch progress vumer initi experi
payer term willing reimburs step edit etc initi real world
kol feedback commerci use
tecfidera ip challeng could expect settlement gener
manufactur similar glenmark sawai last year see chanc
settlement ahead final ipr decis expect februari
walk us view evolv sma competit landscap
see import competit advantag spinraza differ type
sma patient feedback hear kol patient earli
commerci experi zolgensma
ultim opportun envis lupu base recent ph ii
lilac studi result competit profil cutan system lupu vs
market late stage experiment drug latest plan
timelin ph iii studi expect expans rheum/inflamm
psp studi disappoint shape current view role tau
neurodegen diseas abil effect target pathogen tau
monoclon antibodi go forward plan approach
tau excit indic
given recent collabor catalyst around asset dri
previou acquisit nightstar talk grow ophthalmolog
franchis time upcom clinic readout potenti build-out
focu area
effect recent launch mavenclad mayzent ms
product market share key upcom readout develop watch
biib ms franchis protect strategi detail ms day
molecul enhanc remyelin
latest thought approach bd term size potenti deal
therapeut area might pursu increas pace higher
biotech valuat recent influenc view near term
ultim goal biosimilar partnership samsung bioepi
much neg impact biosimilar royalti see initi
would envis longer term
new manag team place view prefer mean
capit deploy evolv rel buyback dividend debt paydown
therapeut area interest addit collabor opportun
outsid gild core expertis expect overal busi strategi differ
vs prior manag
much factor medium-term top- bottom-lin growth rel
diversif cash flow stream preserv play consid potenti busi
develop opportun follow glpg deal size opportun
continu evalu expect addit deal look like similar
partnership-ori structur outright acquisit chang
think build commerci infrastructur filgotinib ahead
potenti approv intern capabl leverag sale team
would expect addit hire need potenti spend next
year launch
view filgotinib competit posit initi ra indic
might expect impact initi uptak label guid overal
commit launch depend spend success result
addit indic expect label follow abbv
upadacitinib approv key area differenti filgotinib
recent rx data suggest rapid uptak descovi sinc prep approv effect
think switch prep market truvada descovi mechan
dispos dtc co-pay card adjust what sens
payers/provid willing prescrib reimburs brand descovi prep
truvada avail gener overal percentag current prep
market believ preserv beyond
follow atla data level commit nash
way leverag commerci infrastructur liver diseas
recent initi sever later-stag studi inject capsid inhibitor
explor nave treatment-resist hiv patient import
overal life cycl strategi read trial design level
confid base on-going work durabl small-volum
subcutan inject far along find suitabl partner
agent taf bictegravir also formul infrequ inject
seen increas pressur payer hiv space introduct
newer competit regimen expect becom greater addit
inject regimen potenti come market introduct gener
descovi updat guidelin price power outsid
recent award damag royalti yescarta
next step legal disput level confid
plan capit deploy car-t/kit platform
royalti potenti impact priorit cell therapi area invest
ip willing settl viiv regard bictegravir patent disput
look move new commerci area diversifi
balanc make necessari invest success long-term margin
view macro environ drug price particularli given
medicar part chang discuss jakafi high public payer
exposur impact decis make price chang jakafi
degre out-year sale goal contempl potenti structur
chang greater challeng reimburs
competit front much impact jakafi seen new
entrant inreb either front-lin share durability/persist jakafi treatment
mf switch altern therapi emerg new data
mf target agent see competit combin
mechan develop compani
mani thing evolv cours includ hire new cfo
increas valuat late-stag oncolog inflamm asset context
think busi develop therapeut area stage
develop and/or deal size view sweet spot potenti in-licens
attract view current valuat product might enabl
leverag exist sale infrastructur accret
respect jakafi life cycl manag bar go/no-go decis
combin pim inhibitor data emerg year
efficacy/safeti balanc differ proceed forward jakafi-refractori
popul vs potenti develop cocktail replac jakafi monotherapi
front-lin standard care much work would need done could
move forward clinic lower dose bet inhibitor level
enthusiasm bet/jak combin
expect see addit data sr formul ruxolitinib
physician payer feedback degre advantag would
need demonstr conveni safeti warrant market convers absent
learn atop dermat market potenti role topic
ruxolitinib phase studi progress forese topic rux
potenti address shortcom previou topic agent ad fit
futur market would expect price agent given differ
popul size ad vitiligo
dermatolog fit regard futur diversif plan
substanti commerci invest would will make new space
think region partnership opportun sale collabor
follow neg data itacitinib chronic gvhd particular
view potenti futur trial design base biomark calca previous
identifi correl treatment success jak inhibitor
key data come year next year help guid whether oral
inhibitor adequ differenti currently-avail
antibodi area tumor type mainten set etc
interest explor drug
addit studi epacadostat still on-going could read year
potenti opportun resurrect program specif cancer
trikafta receiv amongst physician patient give
color around cadenc initi uptak type patient initi
prescrib practic priorit patient initi hurdl
pattern cannib kalydeco orkambi symdeko trikafta
expect homozyg popul base data initi
describ detail paramet around recent uk franc
reimburs agreement confid updat valu assess
methodolog cf agent put ultim maintain accept
price expect base element recent
reimburs agreement eu reimburs process key region
proceed trikafta receiv ema approv trajectori cf product mix
may look rel
expect see addit program cf includ
given data seen trikafta area youd look
improv upon futur modulator-bas cf approach
on-going trial defici proceed clariti ph ii data
timelin on-going safeti updat data clinic preclin elucid
potenti differ
discuss fda follow workshop
sever month ago sort endpoint need look pivot trial
fda talk show clinic endpoint trend right direct
pivot trial clinic endpoint think might abl see earliest
separ expect youd need show statist signific would
trend subgroup secondari endpoint potenti suffic biomark
asid level desmosin pgp might play role assess efficaci
signal establish registr path
speak progress enrol acceler come data
first patient look next data cut
soon expect get sens whether safeti
optim manag novel condit regimen molecular templat
think timelin stem cell deriv approach diabet
semma acquisit enter clinic would
limit factor start clinic studi remind key differ
approach approach
nav-bas pain program still activ expect see
program
come deal across multipl therapeut space think
bd term deal size therapeut stage/area chang overal
busi strategi might expect transit senior leadership
assum eu market approv obtain filgotinib gate factor
abl launch eu geographi glpg respons
discuss payer progress anyth youv abl glean
on-going rinvoq launch use effect promot
talk overal opportun envis filgotinib ibd assum
success on-going ph iii studi uc cd type patient would elig
filgotinib biologic-refractori nave type readout expect
select uc studi top-line pr present medic meet
see bar demonstr competit profil
given inclus adalimumab activ compar arm penguin studi
patient nave bdmard studi power show potenti superior
adalimumab clinicaltri gov list estim complet time-frame
studi could expect see interim data studi
on-going isabela studi ipf inclusion/exclus specif
place minim heterogen diseas progress observ differ
patient natur histori ipf believ potenti mitig
larg sampl size interim analysi expect earli possibl
studi could stop activ potenti stop futil
expect cadenc toledo clinic data readout
addit pk safeti data ph inflammatori marker
tissu gut stool blood etc analyz expect see
signific chang cytokin inflammatori mediat could serv
proof target engag healthi volunt studi type studi
design inclus criteria endpoint length therapi etc envis
upcom studi ibd patient
talk on-going develop antagonist ipf
pure second shot goal ipf mechanist rational
combin approach potenti form could expect
see ph ii pinta data
see potenti fit oa treatment paradigm would
possibl target patient mild-moder diseas attempt prevent
diseas progress expect use sever oa patient
latest thought key pivot endpoint oa pain vs structur vs function
endpoint think design ph iii program
plan bring novel metabol compound
introduc recent day clinic type diabet preclin data
show demonstr counteract benefit provid
metformin synergi addit effect metformin certain
metabol measur youv observ could potenti improv manag
plan implement expand target discoveri technolog
introduc day singl cell analys perform inflam
joint would agnost cell type might target would look
target specif immun cell subset fibroblast
talk strategi ad new drug modal oligo-bas
approach small molecul translat modul protac etc pipelin
balanc extern bd vs develop technolog hous envis
could expect hear first clinic candid emerg new
anyth discuss cours review process believ led
schedul adcomm origin pdufa date updat
pdufa date oca nash base initi fda discuss would
expect key adcomm discuss topic
extens discuss concept dual price oca payer thu
far confid payer recept extent
believ may need discount ocaliva pbc agent launch nash
step youll need take fulli reconcil studi popul oca
nash potenti label popul target advanc fibrosi popul
prescrib payer understand special subgroup intend focu
base discuss continu evolut non-invas diagnost
proport payer cover live believ subject requir
biopsi time oca potenti launch nash addit work
educ around
discuss latest life cycl strategi oca level
confid extend patent exclus beyond would expect life cycl
reli combo next-gen product might greater certainti
around effort
input use determin potenti price oca nash
mention cost nash relat progress cirrhosi
potenti pharmacoeconom data combin preval number youv distil
market research formul price strategi sens
key pressur point payer
base market research includ discuss physician payer
would expect cadenc launch oca nash look degre
expect pent-up demand drive uptak might off-set potenti
access/diagnosi hurdl wait broad use pend outcom data
latest timelin potenti outcom data regener studi
oca nash magnitud benefit might expect given correl
fibrosi stage outcom recently-report sustain liver stiff
improv potenti off-set unfavor effect glycem paramet
lipid measur look sustain favor regener pt date
see potenti complementari competit mechan
develop nash latest strategi explor combo
pbc see respect uptak metric remain
challeng forese adopt
on-going ingrezza launch affect think td market
expect launch/market focu remain awar psychiatrist
educ throughout year addit step take ensur
enter talk broadli payer interact level
confid discount effect rel minor ingrezza year
degre would expect price increas pull increas revenu per
highlight higher-than-expect patient persist ingrezza
expect continu driver initi sign persist
regress toward mean psych- movement-rel drug launch
enrol track huntington studi ingrezza
expect hear materi updat like
sens ingrezza advantag drive major market share td could roll
huntington somewhat off-set lag time market compar austedo
data similar degre would expect potenti class-rel box
label hd indic impact competit posit td
expect orilissa year much contributor
expect out-year
think potenti opicapon approval/launch much expect
new approv comt inhibitor could potenti expand gener use comt-i
amongst physician import believ opicapon
degre familiar opicapon amongst physician could
drive rel rapid start launch interact eu colleagu
driver think import watch opicapon launch
updat program follow call commentari note
encourag fda discuss design/dur detail await
harmon ema registr path anticip use reduct
steroid use endpoint combin biomark thought
enrol requir timelin
import pediatr data program given epidemiolog
diseas sens if/when may see data
think capit alloc particular focu
expand either neuro endocrin vertic specif stage
company/asset would look order best leverag expertis
addit mileston anticip potenti paying/receiv
come complet sunfish trial latest view place
risdiplam may futur sma treatment paradigm think bar
physician adopt agent rel spinraza and/or zolgensma
older type individu younger type pt view still
primari initi address popul untreat individu evolv
follow readout larg respect target popul
kind data expect sunfish data present part
februari key consider compar across trial especi given
differ popul endpoint possibl see hammersmith assist
comparison competitor interpret would expect
especi light differ age rang across studi
talk safeti profil risdiplam placebo-control data
hand particular signal prior studi believ may drug rather
diseas relat updat on-going studi plan implement
teas rate/sever particular side effect signal assum placebo-
control data continu show ophtho find base case ophtho
monitor requir futur label might impact adopt
give clariti time see firefish data risdiplam
form might see top-lin pr present meet etc
view bar competit efficaci set
could provid detail updat screen effort patient
identif aadc defici what level confid base hit rate
among first pt screen meaning address market
evolv sinc screen effort start far along
manufactur run requir gt-aadc approv think
potenti price agent base payer feedback
huntington diseas program stage term ind-en
studi current timelin expect event program like
believ ind file level confid safeti
window pk biodistribut first oral splice modul candid
huntington much preclin work done date tri de-risk safeti
base preclin studi date view huntington diseas
biolog talk level mutant htt knockdown aim
well reduct wild-typ htt healthi volunt ph might translat
mutant htt reduct patient popul pt could potenti move
subsequ could enabl correl biomark efficaci without
overli progress obscur potenti efficaci signal
sens overal registr requir diseas
compar contrast program roche/ioni program other
specif target mutant htt key competit advantag
believ could still way target mutant htt futur
level confid upcom translarna dystrophin data potenti
facilit nda file approv take account prior data agent
potenti variabl biomark recent delay ultim approv srpt
golodirsen kind impact would expect result adopt
europ brazil
see translarna emflaza potenti fit gene therapi dmd
ultim reach market
follow suspens redwood mdd relaps trial paus
recruit rainforest type protocol amend might envis
what statu discuss amend regul degre
believ chang might facilit gener adequ efficaci safeti
data enabl potenti approv use acut treatment mdd
would forese on-going trial resum timelin
readout potenti affect gate factor trial re-initi
given patient rainforest mdd insomnia co-morbid trial alreadi
enrol new amend appli exist patient popul
enough time chang impact trial
current thought strategi first pursu approv
pursu mdd approv afterward what feedback regul
provid potenti exist ph ii/iii efficaci data serv
registr indic addit data might requir
set round safety/retreat profil
sens whether regul might amen view
mountain data context compliant pt measur drug concentr
assum would amen sort strategi could implement
enhanc complianc asid sever center high non-compli rate
mountain featur tast difficulti swallow may
latest thought propos mechan reset
neural circuitri extend period short cours treatment light small
delta vs placebo day mountain provid day placebo-adjust
magnitud ham-d effect optim subgroup vs placebo
given result mountain trial potenti challeng see effect
patient prior medic latest view
amen patient popul addit work would need done
explor dose longer two week dose higher daili
someth might consid explor
key takeaway initi launch zulresso aim
overcom intrins deliveri reimburs challeng
latest metric term number patient treat thu far number certifi center
proport public privat payer set reimburs zulresso
base commerci experi thu far subpopul
expect residu use zulresso approv launch
given recent result wave huntington trial challeng face aso
treat diseas talk think small molecul
fit futur landscap treatment option patient huntington
diseas would expect compet aso modal aim
reduc mutant huntingtin envis combin approach
latest progress develop commerci grade manufactur srp-
still track start confirmatori studi
key remain step achiev commercial-scal manufactur success specif
aspect manufactur program think convinc roch would
capabl suppli global dmd market
current thought design studi recent management
commentari suggest would group studi differ age includ
ambulatori non-ambulatori patient expect cadenc differ
studi start plan initi file base function data expect
ambulatori year old patient studi potenti expand label
function result becom avail differ patient group
patient higher dose gene therapi cohort dose
could expect see biopsi result patient much
abl conclud safeti profil high-dos point thought
commerci manufactur plan clinic develop program
myonexu lgmd gene therapi program
plan present biopsi data microdystrophin patient studi
prior expect function data readout placebo-control year function
data still track report note studi remain blind
safeti event lead studi paus protocol modif
see potenti growth exondi ex-u
region explor exondi expect updat
regulatori progress geographi new roch option opt
ex-u commerci dmd asset influenc current ex-u regulatori
commerci plan exondi vyondi purpos year
wait period roch could exercis option
level confid ppmo pipelin assum success srpt-
sort earli clinic develop timelin envis
ppmo asset similar potenti shorter due learn sad
mad experi ppmo fit priorit given emerg
dmd gene therapi platform
gene therapi program expect begin clinic studi
plan show circul level length follow initi
biomark activ could initi data program includ function
base literatur preclin test rate screen failur due pre-
exist immun expect mpsiii gene therapi program
continu see screen-out microdystrophin lgmd program
idea plan approach patient pre-exist antibodi
research pursu area
degre safeti durabl manufactur data roch examin prior
deal given development cost share roch bolster balanc
sheet roch deal recent loan financ near- mid-term
capit alloc strategi relat opex exist pipelin program
potenti continu extern bd
larg popul mp iiia patient eu area outsid
 eu might target gene therapi chanc
interim/earli look data pivot studi full month data
collect first requir potenti regulatori file
lead follow nda use berotralstat prophylaxi
regulatori feedback influenc level
confid potenti regulatori approv readthrough regulatori
interact see path forward berotralstat acut
step alreadi taken left done prepar potenti
fda approv launch berotralstat regard sale team manufactur
expans launch strategi look like base latest market research
current think price berotralstat given oral conveni
compar safeti efficaci data exist therapi
thought evolv issu time factor regulatori payer kol
feedback etc influenc price strategi
latest thought ex-u commerci strategi berotralstat
whether seek partner eu japan
progress toward complet japanes regulatori requir capit
increas royalti mileston payment
thought potenti explor increas dose berotralstat treat
remain breakthrough event patient preclin studi
safeti higher dose altern
mechanisms/pathway could target conjunct bradykinin pathway
patient breakthrough event
think implic recent ph data show
term clinic respons may abl gener patient
complement diseas like pnh earli data youv gener compar
program pursu factor target
key consider decid dose move forward
given dose signific hemolysi reduct hour
key differ longev effect mg mg hr
bar addit data year
talk safeti profil particular elabor
whether data compar infect risk factor
inhibitor intend monitor may impact patient
treatment confid rash potenti limit factor
previous mention factor level turnov recov quickli
discontinu benefit treatment need paus due
infect quickli expect could play real-world set
would expect patient experi notabl breakthrough symptom miss
dose expect may affect complianc rate
discuss potenti comparison fop program
inhibitor competit program take differ approach
indic ipsen inhibitor/rar-i agonist regn anti-activin mab
broadli expect see year fop program
priorit rel pipelin program like factor
would expect mf data saw broadli translat
larger ph iii popul total symptom score tss respons
lot investor focu baselin characterist cohort
appear chang slightli larger patient popul report
spleen baselin risk score etc appear reflect potenti healthier
popul examin histor comfort studi jakafi
expect jakafi might perform studi popul similar
manifest trial
look patient-by-pati respons rate notic correl
baselin spleen size svr magnitud could indic whether patient smaller
spleen easier harder treat base studi endpoint
sort degrad spleen respons tss endpoint would
expect mark vs data saw
possibl data expand cohort could ultim support
file combo mf given youv alreadi provid ph iii trial
design expect initi next year extra ph ii data serv flesh
true signal combo help inform ph iii powering/enrol requir
discuss fda follow data present
sens whether would amen transfusion-dependence-
base endpoint given histor reluct recogn endpoint
regard safeti profil hear kol
much differenti could clinic use would doc use
respons rate margin better pt significantli less like develop
cytopenia level confid base data cytopenia
cumul worsen treatment cours
base enrol rate/timelin manifest mani patient worth data
would expect time next data cut expect data
eha and/or similar past year
break market opportun success type patient
would expect initi start therapi
plan alloc current capit far expect last
relat expect clinic timelin
enter year multipl potenti pivot readout lenabasum
think data might see resolv ph iii scleroderma studi
term expect criss score well individu compon
shed light power see term criss score result
subcompon criss score believ import
secondari endpoint focu fda given indic discuss
might hope see secondari endpoint given criss
never use primari endpoint scleroderma studi
learn open-label data recent updat
novemb scleroderma dermatomyos expect
scleroderma result remain somewhat stabl last updat
mechanist rational benefit
given chang cf landscap recent month think bar
ph ii data expect summer particular cohort cf
popul believ suit lena use
dermatomyos talk differ exist skin
muscl inflammatori process might affect on-going trial
learn epidemiolog studi expect complet
enrol ph iii
follow kaken partnership earli last year note continu
look asia addit partnership opportun potenti larger market
provid color progress expect achiev
posit safeti profil shown lack effect
expect efficaci bar given context similar rimonab
sort endpoint plan pursu low blood-brain penetr
move forward
indic goal ph program per year start might
shape spend earli lena may still midst develop
multipl indic could advanc may also multipl new
compound mid-lat stage
chief commerci offic compani almost year learn
market research yield plan appli initi launch
plan scleroderma provid color develop
commerci strategi may europ whether chang base
indic lenabasum ultim success
expect key updat either lenabasum indic
 lupu addit indic might explor jenrin compound
highlight day
discuss current progress enrol patient rsvp trial
youv learn popul enrol outlook
complet trial northern hemispher versu add addit
site southern hemispher potenti continu
preval rsv pcr diagnost test current outsid trial set
costli term time infrastructur suppli etc run diagnost
outpati set someon present rsv symptom
discuss ultim market opportun envis
prioriti registration-en popul translat believ
rsvp popul tradit vulner popul children elderli
immunosuppress
latest view mechan inhibit n-protein
 stage especi given multifunct n-protein could
potenti mechanist differ approach offer advantag
discuss kind magnitud effect reduct hbv level
aim ph ia/b studi virem chronic hepat given input kol
potenti regulatori bar might
key differenti featur expect compar core
inhibitor develop plan explor combin hbv
view competit safeti efficaci profil vs oca
drug develop nash thought placebo effect
particularli strong studi compar placebo regener
may led lipid chang observ placebo group
speak develop strategi plan molecul
base entir differ structur expect
progress impact clinic develop
plan priorit rsv hcv nash
discuss futur commerci strategi relat explor partnership
market nash pbc product either abroad
discuss clinic metabol benefit target may provid vs
approach particular focu key differ target
would highlight import metabol chang your look
year readout could provid differenti approach and/or
improv upon aspect therapi develop nash
glycopegyl approach differ modif techniqu
fc fusion whether pk/pd paramet theoret potenti
safety/efficaci differ logist consider manufactur cost
eas product
differenti factor dose time-frame potenc across
differ fgfr-c receptor differ toxic profil focus
would highlight uniqu profil
given recent data nash landscap program lack success
translat fat benefit fibrosi benefit give confid abil
provid long-term posit effect nash concern longer-
look competitor data year guid potenti bar
valid mechan competit posit
dynam look first nash drug launch icpt oca possibl
guid strategi ultim come market
provid color think shtg trial design
upcom ph ii potenti pivot given drug broader mechan
shown repeatedli reduc triglycerid confid level ultim
success shtg view particular cohort within market
like use product like optim differenti price
nash shtg indic
given lag time market shtg compar market therapi
anticip label expans drug like vascepa regard cardiovascular benefit
affect bar competit efficaci earlier biomark
look ahead materi expect shtg top line compar nash
approv indic would expect success failur shtg
meaning affect launch ramp nash given potenti build physician
familiar similar popul
key differenti factor approach stimul
immun system strategi attempt past gener specif
relat cmv havent other use arenavirus clinic applic
especi sinc work well preclin model use research
mani decad
on-going cmv prevent kidney transplant studi
key aspect immunogen look preliminari data readout
reason expect kidney transplant patient would significantli
differ respons vs healthi volunt ph
recruit go kidney transplant studi see potenti
challeng maintain schedul anticip readout talk
rational behind recent addit cmv recipi cohort studi far
might impli safeti well might shape ph iii design enabl
label encompass broader popul
latest thought expand potenti indic beyond
kidney transplant solid organ transplant hematopoiet stem cell
transplant congenit cmv transmiss
recent initi studi cancer talk
rational one intratumor inject follow iv administr cohort
access tumor whether expect one approach yield better
heterolog prime-boost approach expect abl achiev
antigen specif cell human similar youv abl show
preclin model level immun respons like necessari tumor control
view could autoimmun tumor lysi syndrom and/or increas suscept
infect potenti risk robust cancer-specif cell respons
preclin data suggest concern may may problem
talk approach partner take target hiv hbv
would asset design prophylact vaccin immun stimul combat
diseas symptomat infect follow recent announc
continu progress clinic would expect dose
latest develop prostat cancer talk
rational choos antigen make approach plan
perform similar prime-boost techniqu like envis one type
arenaviru would offer enough immun stimul
thought potenti use asset
prophylact vaccin prevent hpv-associ cancer prostat cancer
see rel contribut cell cell antibodi anti-
cmv anti-canc immun hookipa asset differ immun
stimulatori approach regard
launch prepar progress come caplyta approv last
month particularli regard build sale team
view caplyta label differenti antipsychot
market regard popul restrict use safeti point
what feedback physician expect use caplyta
practic rel currently-avail agent given side effect advantag
base
initi payer discuss expect prior author
requir match similar brand antipsychot two step-
gener atyp use case expect
meaning sale begin given potenti delay patient need tri
gener first could patient step quickli enough tri luma
rapidli
give color think price caplyta build
launch framework key consider go decid price
given label
long-term outcom think caplyta
could influenc uptak increas sociabl impact neg symptom
think bipolar depress opportun adjunct data
approach meaning potenti addit bipolar ii patient
opportun comparison bipolar i-specif opportun approv
given file snda bipolar depress given approv
schizophrenia base mix data adjunct data necessarili requir file
bpd could file advanc data readout monotherapi bpd
treatment base result studi timet
might seek fda guidanc
give guidanc around spend trend given dynam
build lumateperon launch well finish bipolar adjunct studi
potenti file indic broadli think cash
runway follow recent financ
expect see addit program
lumateperon major depress cns/movement disord
launch late-lin myeloma popul xpovio progress
import put take drive adopt ae manag physician
and/or patient awar etc safeti efficaci real-world use
compar clinic trial experi
think contract and/or payer interact throughout
xpovio gain traction market expect would affect launch
complianc term patient stay initi
dose label compar expect base trial see
split dose
guid earli key boston data understand studi
event-driven sens whether data might near-term
jan/feb event later would later readout potenti indic
vd arm perform better expect
hear kol bar clinic meaning
boston data term magnitud respons therapi measur
hazard ratio absolut improv well potenti advantag
feasibl reduc velcad dose patient-report improv
provid color around whether boston data
addit interim paramet would look would
safeti mortal would addit interim cost alpha/affect statist
bar success guidanc final data interim data first part
recent file nda selinexor dlbcl nda accept februari
acceler approv would potenti lead label expans
balanc prepar boston data subsequ file dlbcl pathway
materi addit commerci buildout given potenti high overlap
treat physician mm dlbcl vari base academ vs
base number differ treatment dlbcl landscap potenti
switch patient see larger opportun xpovio late-lin
monotherapi combin therapi specif kol
feedback see fit rel car-t distinct
popul might elig therapi could quantifi
aspect efficaci data would highlight import
approv differenti increasingli competit dlbcl landscap
what confid base pre-fil fda interact regulatori bar
open-label data
forum expect see solid tumor data year
 liposarcoma broadli xpovio progress plan look penetr
deeper mm/dlbcl term ad combo ph iii pomalyst come
data even earlier line look diversifi across new indic
recent ceo transit aspect company/area focu
expect chang stay transit proceed
far key element new ceo past experi make
appropri fit job mru
hear kol space decis focu
data youv shown date
epidemiolog fusion seem evolv space studi
better understand preval differ tumor type recent
on-going studi would point topic
latest think develop breast cancer decis
pivot base disappoint mbc result busi
decis might look partner indic could
optim time
youv mention see first data dose escal aml
medic confer confer aim type
amount data could expect
latest updat dose escal proceed
reach feel close monitor paramet
use determin optim dose
thought current treatment paradigm aml see
potenti fit patient on-going studi compar
macrogen studi flotetuzumab present
see bar success
initi clinic studi progress type
tumor expect combin target best suit could
expect see initi data
anticip present initi dose escal data egfr
solid tumor patient tumor colorect expect
show signific activ
latest develop anticip timelin move clinic
next-gen project triclon platform tumor type
diseas could envis tri-specif approach use
context angelman rare untreat diseas
feedback regulatori agenc kol bar success may
neptun import secondari endpoint might
key endpoint view bar clinic meaning
upcom rocket fragil readout prior work give confid
rocket success
level efficaci ph ii work would allow confid
found proper dose angleman insight dose draw
preclin translat work
assum success angelman fragil studi challeng might
expect larger-scal patient identif given current paradigm diagnosi
manag key ex-u geographi
speak expect long term outcom treatment angelman
fragil expect administr therapeut earli enough life
off-set development delay symptom
fragil angelman share certain featur regard present
molecularli clinic thought whether target gaba
address relev defici caus multifacet
light posit trial data explor whether certain
combin current therapi plu particularli effect
two patient low seizur level ineffect two patient
unchang increas potenti combin soc therapi
might mechanist promis view
evalu open-label seizur reduct data key
consider enabl map treatment effect vs natur histori
walk us thought price strategi
interact kol perhap payer regard reimburs
shape current view valu proposit asset
level open potenti collabor partner
develop eu commerci right mean manag opex and/or
secur capit on-going effort
follow recent readout studi forum
expect see addit data present baselin characterist qol endpoint
look toward import updat within data
given differ doublet triplet result particular refer
flatten curv doublet vs continu improv efficaci triplet
elucid effect nesolicaftor think nesolicaftor
wasnt effect combo studi top currently-market doublet
believ mechanist rational nesolicaftor may
addit effect triplet arm wherea prior studi may
less effect broadli go-forward dose tripl
dose use ph ii studi
feedback physician pti cftr asset would fit
cf treatment paradigm differ across geographi
patient commun respond recent ph ii data expect
potenti impact expect enrol timelin upcom studi trikafta
approv eu
note need subject upcom ph iii clinic studi
anoth endpoint addit expect studi design
stage influenc decis
long expect recruit take studi recruit
patient sole driven ex-u enrol plan
target market europe/oth ex-u territori
near-term focu
cf patient rare mutat target choic studi
mani would potenti respond cftr modul
nonsens mutat sort feedback heard kol regard
feasibl organoid approach gener practic
give sens potenti chang go-forward spend rate given initi
ph iii choic studi
still look partner cftr modul program
major characterist youd look partner eu influenc prior cf experi
relev characterist explor preclin whether might
rational combin asset cftr modul develop
talk strategi implement plan implement
promot uptak trogarzo might expect pull
provid color eu market strategi trogarzo think
might similar differ na market strategi began implement
latter half discuss na market strategi meet
expect futur outlook may
speak plan regard expans manufactur
capabl ahead eu launch trogarzo timelin may look like
may affect product avail na market
view anticip launch viiv fostemsavir sens
physician feedback may impact market dynam trogarzo
like see possibl combin therapi line
walk us plan life-cycle extens egrifta provid
updat launch sv formul progress futur
formul may look like may impact ip life-cycle
would abl discuss guidanc insight receiv
fda regard trial design egrifta nash hiv amen
appear futur label expans studi target nash broadli
provid us thought base market research physician
interact see tesamorelin nash hiv potenti fit mani
broader nash product current develop compani
advantag tesamorelin might specif nash hiv
would tesamorelin launch look like futur would expect
impact sale egrifta egrifta sv heard physician payer
feedback might provid insight product roll-out might look like
discuss central cancer biolog preliminari data
could inform whether target downregul cancer cell
promot therapeut resist comment whether seen
therapeut agent target sequest lysosom becom
separ target inactiv lysosom activ
talk us view futur focu pipelin
extend oncolog remain center nash hiv
strategi specif area look expand pipelin
build momentum set forward expect
think nuplazid commerci uptak trend
anticip consid variou patient prescript segment channel
experienc vs new geograph etc expect evolv
see potenti growth nuplazid exist market
latest develop potenti commerci expans ex-u
ex-u region explor
expect regulatori next step drp finer point
place timelin fda engag discuss pimavanserin snda drp
regard harmoni trial drp driver behind implic around
enrol patient enrol respond pimavanserin would higher
dose longer period assess respons see consider work
conduct explor mechan non-respond potenti diagnost
think full data harmoni trial affect estim
address market drp frame awar effort challeng
intrins opportun upsid potenti given drp larg underdiagnos
addit color share regard in-depth sub-group analys
secondari function endpoint analys trial conduct top-line readout
advanc trial schizophrenia-n novemb
term second trial pimavanserin schizophrenia-n plan talk
potenti geograph site plan open trial
fda engag next step share plan thu far
would character nuplazid posit competit landscap
therapeut agent psychosi see nuplazid differenti evolv
overtim compet agent
nuplazid clear potenti platform therapi consider
around rational expans indic asid pdp drp
schizophrenia mdd near-term long-term plan investig efficaci
indic similarli life-cycl plan contempl
key event next month investor look toward
order unlock share valu assist reveal acad underappreci potenti
think moa enabl reactiv protein
variou mutat coval bind caus potenti
toxic safeti concern
think expect efficaci ph iii md trial apr-
benchmark efficaci
proport md patient screen ph iii md trial
due lack mutat issu watch
encount difficulti enrol includ patient
patient characterist mds/mpn cohort ph ii trial apr-
think respons differ much mds/aml popul
proport patient mutat within mpn cohort
cancer patient usual harbor multipl mutat besid think
need use combin agent sequenti order besid md
aml indic think could potenti target
studi design mainten set mani cycl
expect patient receiv transplant long need stay
therapi thought studi design expect basket trial apr-
walk us rational synergi venetoclax
aml think safeti profil differ two cohort inclus
exclus azacitidin recent initi combo trial
without azacitidin plan includ dose ramp-up schedul
venetoclax reach daili
plan timelin next-gener oral reactiv
agent think posit competit landscap oral anti-tumor
agent mds/aml
intellectu properti consider keep mind respect
patent estat ultim commerci lifespan
event specif aprea potenti broader market develop
see import investor help shed light apr valu potenti
attract interest stori
aspect preclin earli clinic character give
confid abil continu translat well clinic
indic high expect evolv patient dose
think differenti context btk inhibitor
screen patient select site activ dose progress sinc last
updat type updat target expect throughout year
would character commerci opportun could
fit treatment landscap inhibitor aml btk inhibitor b-cell
malign consid approv option therapi develop
direct pipelin
cite commerci opportun pipelin popul segment
indic market factor drive shape earli estim
asid safeti toler pk marker track
expect efficaci given sign clinic activ initi ph dose
plan approach time aml/md ph ia/b cohort expect
see chang approach r/r cll/sll nhl patient popul
plan studi design develop combo therapi agent
trial advanc dose-escal key output
time post next step focu patient come onto drug program de-
broad potenti myc oncogen inhibit popul ultim
feasibl pursu beyond current aml md patient set
think relationship efficaci myc inhibit
multitud year-end develop across btk landscap taught
potenti posit program development
commerci
recent instal dr rafael bejar new influenc
expect around map execut on-going plan clinic trial
capabl aptos need order move effici ahead clinic
continu enhanc valu proposit pipelin
given announc acquisit arql hold meet sf
thought consider regard decis time enter
agreement merck around data releas arq
think posit competit landscap chang
acquisit agreement merck affect execut trial
develop plan market potenti
ph ii trial progress date enrol site activ
advanc versu expect propos timelin cours
level detail expect receiv progress oper execut
program
promis data ph trial present expect
hear updat durabl data patient stop
respond plan look cytogenet profil see new mutat
thought potenti combin venetoclax
agent given current observ safeti profil plan
studi look drug interact conduct combin studi
on-going dialogu fda arq major area
discuss high level confid approv agent
pivot trial complet
sinc initi trial progress
compar expect expect hear updat trial
year confid regard timelin top-lin readout
see miransertib posit competit landscap akt inhibitor
develop talk major differenti factor miransertib
compar compet agent
expect see develop miransertib venou malform
base clinic studi result think preclin studi data read-
trial pros/p
think arq differenti akt inhibitor develop
balanc select durabl term design molecul
omibubicel ph iii studi fulli enrol finer point
time expect top-line data procedur involv last patient
enrol transplant measur collect top-line readout
benchmark primari endpoint day neutrophil engraft
omidubicel ph iii trial order show superior clinic benefit standard cord
think overal competit landscap allogen transplant
solut importantli omidubicel fit nam technolog
stand
latest think commerci strategi omidubicel us ex-u
partnership strategi fit approach establish valu
attribut omidubicel transplant technolog import payer
lack standard underutil umbil cord blood
silo practic pattern across medic center play role omidubicel potenti
degre could traction growth haplodent within evolv
transplant space impact overal omidubicel opportun
expect flesh detail around multi-cent multi-dos ph i/ii trial
nam-nk nhl patient popul talk plan studi design
studi latest around design regulatori interact relat
manufactur increasingli critic element cell therapi transplant stori
level confid gmda current manufactur approach suffici
optim clinic commerci stage end-to-end process
manufactur capabl lonza transit proprietari scalabl manufactur
facil progress plan facil
cohort sever aplast anemia stand-alone graft studi omidubicel
progress expect see data look
term preliminari find next step
preclin studi investig gene express profil omidubicel
support sever interest find question think similar studi
nam-nk cell abl answer
asid current on-going omidubicel nam-nk program addit
indic therapeut area think could explor use nam-bas
event excit believ attract investor
interest within development pipelin nam-bas technolog gener
addit color provid driver behind updat guidanc
timelin reveal trial new exist leverag
enrol strategi place help reach enrol year reveal requir
factor involv adjust plan offer top-line efficaci look reveal
expect disclosur could alter
